Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO—Is there any difference? the VITDEX study-Reference-Cited by-同舟云学术

Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO—Is there any difference? the VITDEX study

Published:2022-01-18 Issue:2 Volume:37 Page:280-284
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Iglicki Matias,Busch Catharina^ORCID,Lanzetta Paolo,Sarao Valentina,Veritti Daniele,Rassu Nicolò^ORCID,Lupidi Marco,Cebeci Zafer,Fraser-Bell Samantha^ORCID,Bernal-Morales Carolina^ORCID,Sala-Puigdollers Anna,Zarranz-Ventura Javier^ORCID,Gallego-Pinazo Roberto,Maiti Aniruddha,D’Amico Ricci Giuseppe^ORCID,Udaondo Patricia,Loewenstein Anat,Chhablani Jay^ORCID,Zur Dinah^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://www.nature.com/articles/s41433-022-01931-9.pdf

Reference22 articles.

1. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.

2. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L. et al. Ranibizumab for diabetic macular edema: Results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039.

3. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO. et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. https://doi.org/10.1016/j.ophtha.2011.01.031.

4. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.

5. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016;123:2376–85.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of a dexamethasone implant to treat macular edema following pars plana vitrectomy and removal of the primary epiretinal membrane;International Ophthalmology;2024-08-05

2. Changes in optical coherence tomography biomarkers in eyes with advanced idiopathic epiretinal membrane treated with dexamethasone implantation;BMC Ophthalmology;2024-02-02

3. Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice;Expert Opinion on Drug Safety;2024-01-17

4. Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema;Patient Preference and Adherence;2023-12

5. Accuracy of biomicroscopy, ultrasonography and spectral-domain OCT in detection of complete posterior vitreous detachment;BMC Ophthalmology;2023-11-28